NERVGEN PHARMA CORP.
NGEN$307M
Small CapNASDAQBiotechnology🇺🇸North America
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Mar 15, 2026
5wData is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply
Market Overview
Stock performance and market intelligence
Catalyst Timeline
1 upcoming, 0 past
Phase 2Next
NVG-291 Phase 2 Results Expected
March 2026~NVG-29140
Primary completion for NVG-291 trial (NCT05965700) in Spinal Cord Injuries
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Drug Pipeline
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
NVG-291 | Phase 2 | Spinal Cord Injuries | - |
Regulatory & News
Approvals, filings, and latest developments
Regulatory Approvals
NGEN News